| Prev Close | 139.90 |
| Open | 139.65 |
| Day Low/High | 138.86 / 140.14 |
| 52 Wk Low/High | 118.62 / 148.99 |
| Volume | 3.59M |
Johnson & Johnson (JNJ)
139.55
0.35
0.25
NYSE
| Exchange | NYSE |
| Shares Outstanding | 2662.77B |
| Market Cap | 367.01B |
| Div & Yield | N.A. (N.A) |
Cramer: Buyers for Bristol-Myers Are Few and Far Between
Icahn may have a tough time finding interest in this behemoth.
Takeaways and Observations
Every single market indicator I look at is overbought. But it's likely that shorts and underperformers are buoying stocks. Some are at the most overbought in decades. The bond market is clearly not as sanguine on economic growth/corporate profi...
Health Care ETF Has Been Ailing
You might want to review your holdings in the sector.
Biotech Buoyed by Deal Talk
M&A activity is in a serious upswing, and here are some names to watch.
Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion
Integra hopes this deal will grow its revenue to $2 billion sooner than expected.
Cramer: Why Are People Dumping Such Good Stocks?
Amazon, J&J, IBM and others don't deserve this treatment.
Cramer: Like Them or Not (and I Don't), Bonds Set the Tone Today
They have become a referendum on Trump's plans for lower corporate taxes.
7 Things to Watch in Biotech Now
M&A, drug approvals and Trump are all on my watch list.
The Next Target in Biotech Land
The Actelion buyout opens the way for other deals.
The Next Target in Biotech Land
The Actelion buyout opens the way for other deals.
My Takeaways and Observations
"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...
Jim Cramer: Johnson & Johnson Will Do Well With Actelion
J&J has the potential to 'blow out' Actelion's high blood pressure drug, says Jim Cramer.
News Out of Europe: Johnson & Johnson Buys Actelion
Johnson & Johnson is buying the Swiss biotech Actelion for $30 billion.
Johnson & Johnson Buys Actelion for $30 Billion
Johnson & Johnson plans to spin out Actelion's research and development unit into a separate business.
Johnson & Johnson Still Too Pricey
The most logical path for Johnson & Johnson in the next 12 months appears to be sideways or down.
Rev's Forum: Sometimes a Breakout is Just a Breakout
Too many traders overthink market action rather than embrace the momentum and look for reasons to enjoy the upside.
Global Stocks Are Following Wall Street Higher as Dow Hits 20,000
The Dow Jones Industrial Average took almost 103 years to reach 10,000 in March 1999 and nearly 18 more years to reach 20,000.
Will Johnson & Johnson's Upside Reversal Last?
I'd like to see confirmation of this reversal tomorrow, but now I would "stick my neck out" and write puts.
Cramer: This Rally Is for Real, With Further to Go
Half the Dow components have reported and it's their impressive results that are driving indices up.
Jim Cramer Looks Beyond Dow 20,000
Jim Cramer says the Dow hitting 20,000 is different from previous big runs because the milestone comes during earnings season and allows traders to reevaluate.
Closing Bell: Johnson & Johnson Drags on Health Care; S&P 500, Nasdaq at Records
The Dow Jones Industrial Average sports double-digit gains for the first time in three weeks, moving it closer to 20,000.
The Market Without Memory From Day to Day
Today's market has ignored disappointing profit results at 3M (down $3), Johnson & Johnson (down $3) and Verizon (down $2.50), among others. The "reflation" trade appears to be back (in part a function of several predictable executive orders by ...
Jim Cramer Says J&J's Quarter Wasn't That Bad, but He Can't Jump on Pharma Stocks Right Now
Jim Cramer thought Johnson & Johnson's results were decent but he remains cautious on pharma.
J&J Guides Lower for 2017 Despite Fourth-Quarter Beat
Johnson & Johnson posted better-than-expected fourth-quarter 2016 earnings amid lower 2017 forecasts.
An Uninspiring Start to the Day
The following companies (hat tip Zero Hedge) missed on the top line (sales) this morning (profits weren't much better): Johnson & Johnson MMM DuPont Kimberly-Clark Verizon Again, for emphasis -- beware of the bullish narrative of an improving profit...
Underperformer J&J Does It Again
Dow Jones Industrial Average member Johnson & Johnson is lower in pre-market trading. The reason? The drug maker took a page out of IBM's playbook by recording a much lower effective tax rate in the quarter (14.5% vs. 18%), which on an adjusted basi...
What to Watch Tuesday: Verizon, Lockheed Martin Report Earnings
On Tuesday, January 24, investors await a host of quarterly earnings reports.
What to Watch This Week: Trump's Presidency, Alphabet Earnings
For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.
My Takeaways and Observations (Early Edition)
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
Intermediate Trade: Johnson & Johnson
After an up-and-down year, this household name is as strong as ever.
